MedTrace Logo

Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

NCT04915807 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2021-06-07

No results posted yet for this study

Summary

Real World Data (RWD) obtained from real clinical sites is data obtained after administering a drug to patients with different characteristics in daily practice, and Real World Evidence (RWE) is established based on RWD. It is possible to overcome the disadvantage of RCT, which cannot reflect all the various variables in the actual clinical field as it is conducted for only subset of patients.

Researchers planned to prospectively collect RWD of ramucirumab/paclitaxel combination therapy as 2nd-line chemotherapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Conditions

Interventions

DRUG

Ramucirumab and paclitaxel

Ramucirumab/paclitaxel as a second-line chemotherapy after May 1, 2018, when health insurance coverage for the combination therapy started

DRUG

Taxane, irinotecan, or fluoropyrimidine-based single or combined chemotherapy

Taxane, irinotecan , or fluoropyrimidine-based single or combined chemotherapy as a second-line therapy

Sponsors & Collaborators

  • Hallym University Medical Center

    lead OTHER

Principal Investigators

  • Dae Young Zang · Hallym University Medical Center

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-09-30
Completion
2023-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04915807 on ClinicalTrials.gov